Methods of Treatment Using Anti-IL-17A/F Antibodies
AssigneeUcb Biopharma Sprl
InventorsSophie Glatt, Lucian Ionescu, Margaret Jones, Ruth Oliver, Stevan Graham Shaw, Foteini Strimenopoulou, Venkata Pavan Kumar Vajjah
Life of this patent
Estimating the term…
Abstract
The invention relates to therapeutic uses of antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F in the treatment of dermatological and rheumatological diseases, such as psoriasis, psoriatic arthritis and axial spondyloarthritis.
Claims60
A method of treating psoriatic arthritis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.
(canceled)
A method of treating psoriasis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.
A method of reducing joint effects in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.
32-36. (canceled)
A method of treating rheumatoid arthritis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.
38-58. (canceled)
60-61. (canceled)
(canceled)
65-69. (canceled)
74-82. (canceled)
86-88. (canceled)
90-112. (canceled)
A method of treating axial spondylitis in a human comprising the step of administering to the human a neutralizing antibody which binds human IL-17A and human IL-17F.
115-122. (canceled)
(canceled)
Dependencies are inferred from the claim text.